Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07450378) titled 'QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)' on Feb. 27.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).

Primary Sponsor: Qilu Pharmaceutical Co., Ltd.

Condition: Heterozygous Familial Hypercholesterolemia (HeFH)

Intervention: Drug: QLC7401 Injection

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: May 2026

Target Sample Size: 120

To know more, visit https://clinicaltrials.gov/study/NCT07450378

Published by HT ...